PHAXIAM Therapeutics S.A. Research and Development Expense
PHAXIAM Therapeutics S.A. reported Research and Development Expense of EUR 3.43 million for the 6-month period ending 2023-06-30, per its 6-K filed 2023-09-26.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:ResearchAndDevelopmentExpense · last filed 2023-09-26
| Period end | Research And Development Expense 6 month | Research And Development Expense 12 month |
|---|---|---|
| 2023-06-30 | 3.43M EUR 6-K · filed 2023-09-26 | |
| 2022-12-31 | 19.91M EUR 20-F · filed 2023-03-28 | |
| 2022-06-30 | 17.30M EUR 6-K · filed 2023-09-26 | |
| 2021-12-31 | 45.10M EUR 20-F · filed 2023-03-28 | |
| 2021-06-30 | 23.21M EUR 6-K · filed 2022-09-12 | |
| 2020-12-31 | 57.58M EUR 20-F · filed 2023-03-28 | |
| 2020-06-30 | 28.85M EUR 6-K · filed 2021-09-20 | |
| 2019-12-31 | 52.19M EUR 20-F · filed 2022-04-27 | |
| 2019-06-30 | 22.72M EUR 6-K · filed 2020-09-21 | |
| 2018-12-31 | 33.47M EUR 20-F · filed 2021-03-08 | |
| 2018-06-30 | 16.75M EUR 6-K · filed 2019-09-26 | |
| 2017-12-31 | 25.46M EUR 20-F · filed 2020-03-18 | |
| 2016-12-31 | 19.72M EUR 20-F · filed 2019-03-29 | |
| 2015-12-31 | 10.78M EUR 20-F/A · filed 2018-05-23 |